ReviewInfection2026
Human infections caused by pathogenic Burkholderia: current clinical challenges and future perspectives.
Review in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmaceutical innovation in advanced nanomedicine for the treatment of hypervirulent and multidrug-resistant Klebsiella pneumoniae infections.Archives of microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThe genus Burkholderia comprises diverse environmental bacteria, although only a limited number of species are clinically significant. Among these, Burkholderia mallei, Burkholderia pseudomallei, and the Burkholderia cepacia complex (Bcc) are the primary human pathogens associated with severe infections. This review aims to synthesize current knowledge on these species, focusing on their epidemiology, pathogenicity, diagnostic approaches, and treatment challenges, while identifying key gaps and future research directions.
methodsA narrative synthesis of the literature was conducted, integrating findings from microbiological, clinical, and genomic studies addressing major pathogenic Burkholderia species and their management.
resultsB. mallei causes glanders, a zoonotic infection transmitted through contact with infected animals. B. pseudomallei, an environmental organism endemic to tropical and subtropical regions, causes melioidosis, particularly in individuals with risk factors such as diabetes. The Bcc, comprising over 20 species, poses significant risks in patients with cystic fibrosis and chronic granulomatous disease, where it may lead to severe outcomes including "cepacia syndrome" and nosocomial outbreaks linked to contaminated medical products. Pathogenic Burkholderia species exhibit highly dynamic genomes shaped by horizontal gene transfer, contributing to virulence and intrinsic resistance to multiple antimicrobials, including polymyxins and many β-lactams. Advances in laboratory diagnosis include the use of molecular techniques, mass spectrometry, and whole-genome sequencing alongside conventional methods. Treatment remains challenging due to multidrug resistance, often requiring prolonged and intensive therapeutic regimens.
conclusionsClinically significant Burkholderia species present substantial diagnostic and therapeutic challenges due to their virulence and intrinsic antimicrobial resistance. Improved diagnostic strategies, optimized treatment protocols, and further research into prevention and control measures are essential to mitigate their clinical impact.
Indexed as
Identifiers
41723801What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.